Infections caused by non-tuberculous mycobacteria (NTM) are increasing globally and are
notoriously difficult to treat due to intrinsic resistance of these bacteria to many common …

Mycobacterium abscessus is the second most common nontuberculous mycobacterial lung
disease pathogen and comprises three subspecies: abscessus, massiliense, and bolletii …

Mycobacterium abscessus, a multidrug-resistant nontuberculous mycobacterium, has
emerged as a major pathogen affecting people with cystic fibrosis (CF). Although originally …

Objective For non-tuberculous mycobacteria (NTM), minimum inhibitory concentration (MIC)
distributions of wild-type isolates have not been systematically evaluated despite their …

Background Mycobacterium abscessus (MAB) is the mycobacterial species least susceptible
to antimicrobials. Infections are difficult to treat, and cure rates are below 50% even after a …

Treatment of Mycobacterium abscessus pulmonary infection requires long-term
administration of multiple antibiotics. Little is known, however, about the impact of each …

Rationale: Because the prognosis of nontuberculous mycobacterial pulmonary disease
varies, a scoring system predicting mortality is needed. Objectives: We aimed to develop a …

ABSTRACT SPR720 (phosphate prodrug of SPR719) is a novel aminobenzimidazole
bacterial DNA gyrase (GyrB) inhibitor in development for nontuberculous mycobacterial …

Tuberculosis (TB) drug discovery and development has undergone nothing short of a
revolution over the past 20 years. Successful public–private partnerships and sustained …

Abstract Background The Mycobacterium abscessus complex (MABC) is a difficult to treat
mycobacterium with two distinct morphologies: smooth and rough. As the clinical …